BCR-ABL tyrosine kinase inhibitors
What are BCR-ABL tyrosine kinase inhibitors?
BCR-ABL tyrosine kinase inhibitors inhibit the enzyme BCR-ABL tyrosine kinase, which is important in the pathogenesis of chronic myelogenous leukemia (CML).
Chronic myelogenous leukemia occurs due a single genetic abnormality, known as the Philadelphia chromosome. During the translocation when the Philadelphia chromosome is created, a fusion gene called BCR-ABL gene is formed. The BCR-ABL gene encodes for the BCR-ABL tyrosine kinase. The BCR-ABL positive cells in chronic myelogenous leukemia have increased proliferation and resistance to cell death.
BCR-ABL tyrosine kinase inhibitors are used to treat chronic myelogenous leukemia.
List of BCR-ABL tyrosine kinase inhibitors:
|Drug Name||Avg. Rating||Reviews|
Generic name: imatinib
Generic name: nilotinib
Generic name: dasatinib
Generic name: bosutinib
Generic name: ponatinib
Generic name: asciminib
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|
Medical conditions associated with BCR-ABL tyrosine kinase inhibitors:
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.